Do MTHFD1 and MTRR variants make low folate more likely to impair DNA synthesis and red blood cell maturation?

Genetic disruption of one-carbon metabolism

• Enzymatic impairment: The MTHFD1 rs2236225 (R653Q) variant alters cytosolic C1-THF synthase, resulting in a thermolabile enzyme with a ~50% reduction in 10-formyl-THF synthetase activity. This decreases de novo purine synthesis and one-carbon flux.
• Remethylation deficits: The MTRR rs1801394 (A66G) polymorphism reduces the efficiency of methionine synthase reductase in restoring methionine synthase (MTR) to its active catalytic state, limiting the remethylation of homocysteine to methionine.
• Loss of network resilience: Together, these variants act as hypomorphic nodes that limit the metabolic buffering capacity of the pathway, lowering S-adenosylmethionine (SAM) levels and elevating homocysteine under nutritional or metabolic stress.

Impacts on DNA synthesis and red blood cell maturation

• Nucleotide depletion: Folate deficiency limits 5,10-methylenetetrahydrofolate, the key substrate for de novo thymidylate (dTMP) synthesis. This restriction impairs DNA replication and drives uracil misincorporation.
• Genomic instability: Excessive uracil in DNA triggers base-excision repair. In folate-deficient states, this repair process leads to double-strand breaks, replication stress, and severe DNA synthesis impairment.
• Ineffective erythropoiesis: Delayed nuclear maturation, combined with ongoing cytoplasmic development in erythroblasts, causes megaloblastic and macrocytic red blood cell maturation defects.
• Compromised protective buffering: Under normal conditions, MTHFD1 translocates to the nucleus during S-phase to prioritize dTMP synthesis and protect genomic integrity. Genetic variants in MTHFD1 and MTRR compromise this protective mechanism, leaving erythroid precursors highly vulnerable to even marginal folate deficiency.

Bottom line

• MTHFD1 and MTRR variants structurally weaken the one-carbon metabolic network. This genetic vulnerability directly impairs the body's ability to buffer against low folate levels, significantly increasing the risk of defective DNA synthesis, genomic instability, and macrocytic anemia.